DUBLIN, Ireland, Aug. 30, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development, and commercialization of novel protein immunotherapies, today announced that members of its senior management team will present and participate in several upcoming investor conferences:
- Credit Suisse Antibody Day on September 7, 2016 at 12:00 PM ET in New York, NY
- Citi’s 11th Annual Biotech Conference on September 8, 2016 in Boston, MA
- Morgan Stanley Global Healthcare Conference on September 12, 2016 at 8:45 AM ET in New York, NY
- The Ladenburg Thalmann 2016 Healthcare Conference on September 27, 2016 at 10:00 AM ET in New York, NY
A live webcast of the company presentations can be accessed under the Investors tab in the Events and Presentations section of the Company's website at www.prothena.com. Following the live presentations, a replay of each webcast will be available on the Company's website for at least 90 days following the presentation date.
Prothena Corporation plc is a global, late-stage clinical biotechnology company seeking to fundamentally change the course of progressive diseases with its clinical pipeline of novel therapeutic antibodies. Fueled by its deep scientific understanding built over decades of research in protein misfolding and cell adhesion — the root causes of many serious or currently untreatable amyloid and inflammatory diseases — Prothena has advanced several drug candidates into clinical trials while pursuing discovery of additional novel therapies. Our pipeline of antibody-based product candidates targets a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002) and inflammatory diseases, including psoriasis (PRX003), and ATTR amyloidosis (PRX004). For more information, please visit the company's web site at www.prothena.com.
For more information, please visit the company's web site at www.prothena.com.
Source:Prothena Corporation Plc